Affiliation:
1. Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Abstract
One of the factors of variability of malignant neoplasms is the loss of heterozygosity (LOH). The biological meaning of LOH, in relation to carcinogenesis, is associated with the inactivation of heterozygous loci of pathogenetically significant genes. Thus, the aim of this work was to study BRCA1/2 LOH in breast tumors.Material and Methods. The study included 122 patients with stage IIAIIIC breast cancer. DNA was isolated from 122 biopsy samples of tumor tissue using the QIAamp DNA mini Kit (Qiagen, Germany). To assess the status of LOH, microarray analysis was performed on high-density DNA chips from Affymetrix CytoScanTM HD Array. To process the results of microchipping, we used the Chromosome Analysis Suite 3.3 program (Affymetrix, USA).Results. The loss of heterozygosity in the BRCA1 gene was found to be associated with response to NAC. It was shown that in 59 patients LOH in the BRCA1gene was associated with an objective response to treatment (p=0.005). The presence of LOH in the studied genes was associated with a favorable prognosis. The 5-year non-metastatic survival rates were 75 % and 100 % in patients with LOH in the BRCA1 and BRCA2 genes, respectively (log-rank test: p=0.003 and p=0.05, respectively).Conclusion. The phenomenon of LOH in the BRCA1/2 genes was shown to be associated with response to NACT. BRCA1/2. Further studies are needed to evaluate the frequency of BRCA1/2 LOH after NAC for choosing and changing treatment tactics.
Publisher
Tomsk Cancer Research Institute
Reference15 articles.
1. Ryland G.L., Doyle M.A., Goode D., Boyle S.E., Choong D.Y., Rowley S.M., Li J., Bowtell D.D., Tothill R.W., Campbell I.G. Loss of heterozygosity: what is it good for? BMC Med Genomics. 2015; 8: 45. doi: 10.1186/s12920-015-0123-z.
2. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences. 1971; 68(4): 820–823.
3. Chen Y., Chen C. DNA copy number variation and loss of heterozygosity in relation to recurrence of and survival from head and neck squamous cell carcinoma: a review. Head Neck. 2008; 30(10): 1361–83. doi: 10.1002/hed.20861.
4. Silva J.M., Silva J., Sanchez A., Garcia J.M., Dominguez G., Provencio M., Sanfrutos L., Jareño E., Colas A., España P., Bonilla F. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clinical Cancer Research, 2002; 8(12): 3761–3766.
5. Okudela K., Tateishi Y., Umeda S., Mitsui H., Suzuki T., Saito Y., Woo T., Tajiri M., Masuda M., Miyagi Y., Ohashi K. Allelic Imbalance in the miR-31 Host Gene Locus in Lung Cancer-Its Potential Role in Carcinogenesis. PLoS One. 2014 Jun 30; 9(6): e100581. doi: 10.1371/ journal.pone.0100581.